EGFR and paronychia: Cutaneous reactions similar to the adverse events caused by EGFR inhibitors (RAF mediates EGFR signaling pathways) are present in 74% of the patients [50] and include dose dependent papulopustular rash (18% of the patients taking vemurafenib, 27% of those dabrafenib) [81,82], photosensitivity (12% of the patients taking vemurafenib) [82], xerosis, pruritus, paronychia [80], alopecia and hair follicle alterations, hyperkeratosis [77], pyogenic granulomas [24,29].